NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced a presentation at the American Academy of Ophthalmology (AAO) 2024 Expo, ...

NEW YORK - Eyenovia, Inc. (NASDAQ: NASDAQ:EYEN), an ophthalmic technology firm, has announced the U.S. commercial availability of its FDA-approved clobetasol propionate ophthalmic suspension 0.05% ...

Despite a significant net loss, Eyenovia Inc (EYEN) progresses with innovative technologies and promising collaborations in ...

Sodium lauryl sulfate, a common ingredient used to make toothpaste foamy, has been linked to longer-lasting, more-painful ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced that the Company has commenced manufacturing of registration batches of its ...

A clinical diagnosis was made of psoriasis and he was prescribed clobetasol propionate ointment with salicylic acid 6% in petrolatum that should be applied in the evening to his elbows and knees ...

One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...

The Company intends to use the net proceeds from the offering to fund commercialization activities for Mydcombi and clobetasol propionate, complete the CHAPERONE pediatric myopia clinical study ...

The agreement with Singular has provided strategic business consulting, product development, and brand marketing services to Lifeist and its operating divisions during a critical period of time for ...

Topical/skin directed therapies are best for early-stage disease or in combination with systemic therapies in advanced disease, according to Dr Arron Mangold.